Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2024 · View financials
Decision snapshot: AZZ stock price vs MRSN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MRSN's multiple
Needs MRSN P/E.
Implied fair value · at AZZ's multiple
Needs EPS (TTM) is negative, AZZ P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AZZ FY 2026 (ended Feb 28, 2026) · MRSN FY 2024 (ended Dec 31, 2024). Fiscal years are not aligned.
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
AZZ Inc. · implied price per share
Bear
$127.99
Base
$150.57
Bull
$173.16
Mersana Therapeutics, Inc. · implied price per share
Bear
$12.48
Base
$14.68
Bull
$16.88
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.45x
-2.47x
Net debt / EBITDA
Leverage against operating earnings
0.99x
2.89x
Cash and equivalents
Liquid reserves on the balance sheet
$705.00K
$195.89M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$602.74M
$23.45M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe AZZ can sustain its current earnings quality and remain within its historical valuation band, then holding or accumulating on pullbacks makes sense because AZZ combines 14.3x P/E, 8/9 F-Score, and 4.86 Altman Z-Score with solid profitability.
AZZ trades at 14.3x P/E and 2.7x P/S, which is consistent with a profitable industrial business rather than a deep discount or obvious premium. Its current price of $150.01 sits inside the historical band of $135.01 to $165.01 and below the midpoint of the DCF range, suggesting fair-to-slightly-undervalued positioning versus intrinsic estimates.
Supporting Metrics
